News center

Thank you for your interest in HUIZHONG

News center
General Search
keyword :

Your present location:Home >> News center >> Main content
Main content

"New flow method triple inactivated vaccine" by the national new veterinary certificate

Number of visits: Date:2017-08-01 12:06:31

Abstract:

According to the "Regulations on the Administration of Veterinary Drugs" and the "Veterinary Drug Registration Regulations", the Ministry of Agriculture has reviewed and approved the Pulike Biology, Luoyang Huizhong Biology and other common declaration of "Newcastle disease, avian influenza (H9 subtype),

According to the "Regulations on the Administration of Veterinary Drugs" and the "Veterinary Drug Registration Regulations", the Ministry of Agriculture has reviewed and approved the Pulike Biology, Luoyang Huizhong Biology and other common declaration of "Newcastle disease, avian influenza (H9 subtype), infectious bursal disease triple inactivation Vaccine (La Sota strain + SZ strain + rVP2 protein) "as a new veterinary drug, and on May 18, 2017 the Ministry of Agriculture website announced the issuance of" new veterinary drug registration certificate "(Ministry of Agriculture Notice No. 2525) matters.

The product was submitted to the Ministry of Agriculture for the first time on October 10, 2014, the clinical trial application, the follow-up clinical trials, new veterinary drug registration and other stages, the Ministry of Agriculture on May 18, 2017 issued a new veterinary drug registration certificate.

Chicken Newcastle disease, avian influenza (H9 subtype) and infectious bursal disease are serious harm to our country and the world chicken industry, an important disease. Because of its wide range of epidemic, high morbidity, mixed infection under the high mortality rate, has been to the world of chicken industry caused huge economic losses, and vaccine immunization is an important measure to prevent these three diseases.

Up to now, only one domestic production of these products, the company jointly developed by other units of the chicken Newcastle disease, avian influenza (H9 subtype), infectious bursal disease triple inactivated vaccine (La Sota strain + SZ strain + rVP2 protein) The following advantages: First, this product used in the H9 subtype avian influenza vaccine strains with antigen cross-protection spectrum of the advantages of the current epidemic strains can produce better immune protection; the second is the use of genetic engineering means, the use of E. coli expression system Expression of chicken infectious bursal disease virus VP2 protein, high purity VP2 protein can be spontaneous assembly into virus capsular-like particles, effectively improve the immune effect; Third, by optimizing the purification process technology, significantly reduce endotoxin residues, to further improve the vaccine The security of the.

The new veterinary drug certificate is the company continued to attach importance to scientific and technological innovation, increase R & D investment results, and further reflects the company's innovative strength, but also to promote the industry poultry vaccine products upgrading, maintaining the company in the poultry market vaccine innovation Leading position, and effectively enhance the company's overall competitiveness in the industry, the company will bring new performance growth.

TypeInfo: Company news

Keywords for the information:

Email: export@huizhongsy.com.cn Tel: +86 0379-61123578
Add: No.15 Zhenghe Road, Luolong District, Luoyang City, Henan Province
豫ICP备11017935号 TECHNICAL SUPPORT BY YICHANG.300.CN